Celldex Therapeutics Inc

Company Profile

Celldex Therapeutics Inc had its IPO on 1990-03-26 under the ticker symbol CLDX.

The company operates in the LIFE SCIENCES sector and IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry. Celldex Therapeutics Inc has a staff strength of 0 employees.

Stock update

Shares of Celldex Therapeutics Inc opened at $35.34 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $34.55 - $36.52, and closed at $34.58.

This is a -2.18% slip from the previous day's closing price.

A total volume of 376,722 shares were traded at the close of the day’s session.

In the last one week, shares of Celldex Therapeutics Inc have increased by +1.71%.

Celldex Therapeutics Inc's Key Ratios

Celldex Therapeutics Inc has a market cap of $1.617 billion, indicating a price to book ratio of 4.544 and a price to sales ratio of 1965.24.

In the last 12-months Celldex Therapeutics Inc’s revenue was $0.001 billion with a gross profit of $-0.049 billion and an EBITDA of $-0.088 billion. The EBITDA ratio measures Celldex Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Celldex Therapeutics Inc’s operating margin was -11097% while its return on assets stood at -18.8% with a return of equity of -36.4%.

In Q2, Celldex Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 95.3%.

Celldex Therapeutics Inc’s PE and PEG Ratio

Forward PE

-

Trailing PE

-

PEG

0

Its diluted EPS in the last 12-months stands at $-1.725 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Celldex Therapeutics Inc’s profitability.

Celldex Therapeutics Inc stock is trading at a EV to sales ratio of 1587.13 and a EV to EBITDA ratio of -14.8. Its price to sales ratio in the trailing 12-months stood at 1965.24.

Celldex Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$0.000 billion

Total Liabilities

$0.000 billion

Operating Cash Flow

$0.000 billion

Capital Expenditure

$0.000 billion

Dividend Payout Ratio

0%

Celldex Therapeutics Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Celldex Therapeutics Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Celldex Therapeutics Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Celldex Therapeutics Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Celldex Therapeutics Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price

$34.58

52-Week High

$46.8

52-Week Low

$19.85

Analyst Target Price

$65.17

Celldex Therapeutics Inc stock is currently trading at $34.58 per share. It touched a 52-week high of $46.8 and a 52-week low of $46.8. Analysts tracking the stock have a 12-month average target price of $65.17.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.